The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 24, 2018

Filed:

Mar. 30, 2012
Applicants:

Martin Pomper, Baltimore, MD (US);

Zaver Bhujwalla, Baltimore, MD (US);

Zhihang Chen, Baltimore, MD (US);

Cong LI, Baltimore, MD (US);

Sridhar Nimmagadda, Baltimore, MD (US);

Marie-france Penet, Baltimore, MD (US);

Sangeeta Ray, Ellicott City, MD (US);

Inventors:

Martin Pomper, Baltimore, MD (US);

Zaver Bhujwalla, Baltimore, MD (US);

Zhihang Chen, Baltimore, MD (US);

Cong Li, Baltimore, MD (US);

Sridhar Nimmagadda, Baltimore, MD (US);

Marie-France Penet, Baltimore, MD (US);

Sangeeta Ray, Ellicott City, MD (US);

Assignee:

THE JOHNS HOPKINS UNIVERSITY, Baltimore, MD (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61B 10/00 (2006.01); A61B 5/00 (2006.01); A61B 8/00 (2006.01); A61K 51/08 (2006.01); A61K 47/48 (2006.01); A61K 49/00 (2006.01); A61K 49/12 (2006.01); A61K 51/06 (2006.01); A61K 9/00 (2006.01); C12N 15/113 (2010.01); A61K 31/513 (2006.01); A61K 31/713 (2006.01); A61K 38/50 (2006.01);
U.S. Cl.
CPC ...
A61K 51/083 (2013.01); A61K 9/0019 (2013.01); A61K 31/513 (2013.01); A61K 31/713 (2013.01); A61K 38/50 (2013.01); A61K 47/48138 (2013.01); A61K 47/48192 (2013.01); A61K 47/48215 (2013.01); A61K 47/48315 (2013.01); A61K 47/48884 (2013.01); A61K 49/0032 (2013.01); A61K 49/0054 (2013.01); A61K 49/126 (2013.01); A61K 51/065 (2013.01); C12N 15/113 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2320/30 (2013.01); C12N 2320/32 (2013.01);
Abstract

The present invention provides targeted nanoplex molecules which carry multimodality imaging reporters together with target enzyme inhibitors such as siRNAs and target prodrug enzymes, that are useful for theranostic imaging of cells and diseases, including, for example, various cancers, and including metastatic prostate cancer. The nanoplex molecules of the present invention provide a platform technology toward many cancer subtypes and alternative therapeutic targets. Downregulation of specific pathways using targeted enzyme inhibitors further provides unique opportunities to target cancer cells selectively while sparing normal tissue. The nanoplex molecule platform described herein has the ability to deliver multiple siRNA enzyme inhibitors. Methods of diagnosis and treatment of various diseases are also included. The strategy described herein can be useful to down-regulate multi-drug resistance pathways, or repair enzymes with the goal of increasing the efficacy, safety, and efficiency of chemotherapeutic or irradiation therapies.


Find Patent Forward Citations

Loading…